metronidazole · Alembic Therap · NDA 205223
Nuvessa
Earliest generic entry, as listed
28 Jun 2032
Blocked by patent: US 10238634, US 10596155, US 8946276, US 9198858.
Listed patents · 7 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10238634 | drug product · sets the listed date | 28 Jun 2032 |
| US 10596155 | drug product · sets the listed date | 28 Jun 2032 |
| US 8946276 | use U-1664 · sets the listed date | 28 Jun 2032 |
| US 9198858 | use U-1664 · sets the listed date | 28 Jun 2032 |
| US 8658678 | use U-1682 | 27 Jun 2028 |
| US 7893097 | drug product | 19 Feb 2028 |
| US 8877792 | drug product | 2 Feb 2028 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 205223 · 001 · RLD | gel, vaginal | 1.3% | 28 Jun 2032 |